Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

Arthritis and Rheumatism
Kurt RedlichGeorg Schett

Abstract

To study the effects of osteoclast-targeted therapies, such as osteoprotegerin (OPG) and pamidronate, on joint inflammation and bone destruction using a tumor necrosis factor alpha (TNF alpha)-transgenic mouse model. Mice were placed into 5 groups that received either OPG, pamidronate, a combination of both agents, infliximab as a positive control, or phosphate buffered saline as a negative control. Treatment was initiated at the onset of arthritis, continued over 6 weeks, and thereafter, the clinical, radiologic, and histologic outcomes were assessed. A significant improvement in clinical symptoms, as assessed by the reduction of paw swelling, was only found in the infliximab group, whereas all other treatment groups failed to show significant improvement. However, when assessing structural damage with radiographic analysis, a significant retardation of joint damage was evident in animals treated with OPG (55% reduction of erosions), pamidronate (50% reduction of erosions) the combination therapy of OPG and pamidronate (64% reduction of erosions), and with infliximab (66% reduction of erosions). Confirming these data, quantitative histologic analysis revealed a significant reduction in the size of bone erosions in all treatmen...Continue Reading

References

Jan 1, 1987·Scandinavian Journal of Rheumatology·A Larsen, J Thoen
Jan 1, 1986·Annals of the Rheumatic Diseases·A BarbierR Roncucci
Sep 1, 1984·Arthritis and Rheumatism·M Bromley, D E Woolley
Jan 1, 1994·Scandinavian Journal of Rheumatology·A MaccagnoA Perez Lloret
Jan 1, 1996·Annual Review of Immunology·M FeldmannR N Maini
Dec 6, 1997·Biochemical and Biophysical Research Communications·H TakayanagiY Koshihara
Mar 14, 1998·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·M W PysklywecE R Bogoch
May 23, 1998·Annual Review of Pharmacology and Toxicology·G A Rodan
Nov 13, 1998·Proceedings of the National Academy of Sciences of the United States of America·A V MiagkovS S Makarov
Dec 4, 1998·Springer Seminars in Immunopathology·F M BrennanM Feldmann
Dec 4, 1998·Springer Seminars in Immunopathology·C Gabay, W P Arend
Mar 19, 1999·Biochemical and Biophysical Research Communications·N TakahashiT Suda
May 18, 1999·Rheumatology·G SteinerJ S Smolen
Sep 1, 1999·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·S MoronyC R Dunstan
Feb 15, 2000·The Journal of Biological Chemistry·Y AzumaA Kudo
Feb 29, 2000·Arthritis and Rheumatism·E M GravalleseS R Goldring
May 10, 2000·Current Opinion in Rheumatology·S R Goldring, E M Gravallese
Jun 30, 2000·The Journal of Biological Chemistry·Y Abu-AmerS L Teitelbaum
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Mar 30, 2001·Novartis Foundation Symposium·T SudaN Takahashi

❮ Previous
Next ❯

Citations

Jun 24, 2010·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·S Ferrari-Lacraz, S Ferrari
Sep 6, 2011·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·N B WattsS Ferrari
Jun 19, 2013·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M VisW F Lems
Jan 1, 2008·Reviews in Endocrine & Metabolic Disorders·Anuradha Viswanathan, Francisco A Sylvester
Mar 23, 2004·Biochemical and Biophysical Research Communications·Taeko IshiiYukihiko Saeki
Aug 26, 2006·Nature Clinical Practice. Rheumatology·Georg SchettJosef S Smolen
Mar 2, 2012·Nature Reviews. Drug Discovery·Kurt Redlich, Josef S Smolen
Oct 3, 2009·Nature Reviews. Rheumatology·Yongwon ChoiMichael J Townsend
Sep 26, 2012·Nature Reviews. Rheumatology·Georg Schett, Ellen Gravallese
Apr 23, 2003·Current Opinion in Rheumatology·Tomoki NakashimaJosef M Penninger
Jun 24, 2003·Current Opinion in Rheumatology·Petros P Sfikakis, George Kollias
Jun 24, 2003·Current Opinion in Rheumatology·Glenn HaugebergTore K Kvien
Jun 18, 2004·Current Opinion in Rheumatology·Nicole C Walsh, Ellen M Gravallese
Jun 10, 2006·Current Opinion in Rheumatology·Brendan F BoyceLianping Xing
Jun 7, 2007·Current Opinion in Rheumatology·Eric Toussirot, Daniel Wendling
May 2, 2012·Infection and Immunity·Romina ScianM Victoria Delpino
Feb 14, 2004·Annals of the Rheumatic Diseases·J S Smolen, D Aletaha
May 22, 2007·Annals of the Rheumatic Diseases·Georg SchettDésirée van der Heijde
Nov 20, 2002·The Journal of Clinical Investigation·Kurt RedlichGeorg Schett
Mar 18, 2003·The Journal of Clinical Investigation·Christopher T RitchlinEdward M Schwarz
May 9, 2006·The Journal of Clinical Investigation·Kazuhiro AokiRoland Baron
Feb 24, 2007·Arthritis Research & Therapy·Georg Schett
Jul 20, 2007·Arthritis Research & Therapy·Georg Schett
Aug 25, 2011·Arthritis Research & Therapy·Tobias Braun, Jochen Zwerina
Aug 23, 2003·Arthritis Research & Therapy·Georg SchettJosef S Smolen
Aug 27, 2009·Biologics : Targets & Therapy·E Michael Lewiecki
Apr 29, 2009·The Keio Journal of Medicine·Steeve Kwan TatJohanne Martel-Pelletier
May 7, 2005·Indian Journal of Medical Sciences·S M Akerkar, L S Bichile

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here